News
GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support ...
GSK PLC closed 11.51% short of its 52-week high of £16.79, which the company achieved on September 9th.
GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...
GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...
GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...
GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...
3d
Pharmaceutical Technology on MSNBharat Biotech acquires licence for GSK’s Shigella vaccine developmentGSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...
GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...
GSK PLC GSK shares dropped 2.45% to £15.12 Friday, on what proved to be an all-around poor trading session for the stock ...
India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five ...
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results